Is NAD FDA Approved? What Consumers Should Know

NAD+ (nicotinamide adenine dinucleotide) is not an FDA-approved drug for any condition, and its regulatory status as a supplement is surprisingly complicated. One of its most popular precursors, NMN, was effectively banned from sale as a dietary supplement by the FDA in late 2022, while another precursor, nicotinamide riboside (NR), remains legally sold in supplement form. The distinction matters because what you can buy, what has been tested, and what the FDA has weighed in on are three very different questions when it comes to NAD+ products.

Why NAD+ Is Not FDA Approved

The FDA approves drugs, not molecules in the abstract. For a substance to earn FDA approval, a company must run large-scale clinical trials proving the drug is safe and effective for a specific disease, then submit that data for review. No company has completed this process for NAD+ itself or for any NAD+ precursor as a treatment for aging, fatigue, cognitive decline, or any of the other conditions commonly advertised by supplement and IV-therapy companies. The products you see online and in clinics exist in a regulatory gray zone between food supplements and pharmaceuticals.

NAD+ is a coenzyme found in every living cell. It is central to energy metabolism and also serves as a cofactor for enzymes involved in DNA repair, immune function, and cellular aging processes.¹ Because it is a naturally occurring molecule rather than a novel compound, it does not fit neatly into the FDA’s drug approval pipeline. Companies selling NAD+ products have instead tried to market them as dietary supplements, which face far less regulatory scrutiny. But that strategy has its own problems.

The NMN Ban and What It Means

In November 2022, the FDA declared that beta-nicotinamide mononucleotide (NMN) could no longer be sold as a dietary supplement in the United States. The reasoning came down to timing: a company called Metro International Biotech had already begun investigating a proprietary form of NMN (called MIB-626) as a new drug before NMN was widely marketed as a supplement. Under the Federal Food, Drug, and Cosmetic Act, once a substance is authorized for investigation as a new drug and substantial clinical trials are underway, it can be excluded from the supplement category.²

This did not mean NMN was declared unsafe. It meant the FDA drew a line between supplements and drugs, and NMN landed on the drug side of it. In practice, many NMN products are still sold online, often shipped from overseas or marketed in ways that skirt the ruling. But technically, selling NMN as a dietary supplement in the U.S. violates federal law as it currently stands. The FDA has not aggressively enforced the ban, which creates confusion for consumers who still see NMN products everywhere.

Nicotinamide riboside (NR), on the other hand, was not affected by the same ruling. NR had already been marketed as a supplement before any drug investigation began, so it retained its supplement status. This is why NR-based products like Tru Niagen remain widely available in stores and online, while NMN technically cannot be sold the same way.

What NAD+ Precursors Actually Do in the Body

You cannot simply swallow a pill of NAD+ and expect it to reach your cells intact. NAD+ is a large molecule that does not survive digestion well. Instead, the supplement industry relies on precursors, smaller molecules that your body converts into NAD+ after absorption. The main precursors are NMN, NR, niacin (vitamin B3), and nicotinamide. Each follows a different biochemical route to become NAD+.³

The interest in boosting NAD+ stems from a straightforward observation: NAD+ levels drop as you age. Studies measuring NAD+ in human tissue have found a clear negative correlation between age and NAD+ content, with levels falling progressively from birth through old age in both men and women.⁴ This decline matters because NAD+ fuels a family of enzymes called sirtuins, which regulate glucose and fat metabolism, mitochondrial function, and inflammatory signaling. When NAD+ drops, sirtuin activity drops with it.⁵

The logical question is whether restoring NAD+ to youthful levels reverses or slows aging-related decline. That question has been answered convincingly in mice but remains far less clear in humans.

Do NAD+ Supplements Raise NAD+ Levels in Humans?

Yes, and this part of the story is well established. In a randomized, placebo-controlled trial, healthy overweight adults who took NR at doses of 100, 300, and 1,000 mg per day saw their blood NAD+ levels rise by roughly 22%, 51%, and 142% respectively within two weeks. Those increases held steady through the end of the eight-week study.⁶ Across multiple trials, both NR and NMN supplementation have been shown to safely and tolerably increase NAD+ and related metabolites in various tissues.⁷

Raising NAD+ levels is the easy part. The harder question is whether that biochemical change translates into anything you would actually feel or benefit from.

What the Clinical Trials Show (and Don’t Show)

The human evidence for NAD+ precursors is a patchwork of small trials testing different compounds, doses, populations, and outcomes. Some results are intriguing. Others are underwhelming. None are definitive enough to support the sweeping anti-aging claims you see in supplement marketing.

On insulin sensitivity and metabolic health, a study in prediabetic women who were overweight or obese found that NMN supplementation improved muscle insulin sensitivity and insulin signaling compared to placebo.⁸ A trial in healthy middle-aged Japanese men found that NMN safely boosted NAD+ and modestly reduced postprandial hyperinsulinemia in a small subset of participants who had elevated insulin after eating, though the subset was just three people.⁹ A placebo-controlled trial of 250 mg NMN daily in middle-aged and older adults showed that fasting glucose fell about 4% in the supplement group while rising about 6.5% in the placebo group, though the difference in insulin resistance between groups was not statistically significant.¹⁰

For cardiovascular markers, a randomized trial found that NMN supplementation tended to decrease arterial stiffness, but the overall difference between supplement and placebo groups was not significant. The effect was more pronounced in the subgroup with higher BMI or blood glucose levels.¹¹

On physical performance, a study in amateur runners found that medium and high doses of NMN increased ventilatory threshold power and oxygen uptake during exercise over six weeks. But the supplement did not improve peak power or maximum oxygen consumption, which are the markers most people care about when thinking about athletic performance.¹²

One of the more interesting recent findings involves brain health. In a trial of older adults with subjective cognitive decline or mild cognitive impairment, NR supplementation led to a 7% reduction in pTau217, a blood biomarker associated with Alzheimer’s disease pathology, while the placebo group saw an 18% increase. No significant differences were found on cognitive test scores themselves.¹³ A biomarker moving in the right direction is encouraging, but a biomarker is not the same thing as a clinical outcome. People want to know if they will remember their grandchildren’s names, not what their pTau217 level is.

The honest summary of the trial landscape: NAD+ precursors reliably raise NAD+ levels, and small trials suggest modest benefits in metabolic markers, exercise capacity, and possibly brain biomarkers. But no large-scale trial has shown that NAD+ supplements prevent or reverse any disease, extend lifespan, or produce the dramatic rejuvenation effects promised in much of the marketing.

IV NAD+ Therapy Is a Different Story

Walk into certain wellness clinics, and you can pay several hundred dollars for an intravenous infusion of NAD+ itself, bypassing the digestion problem entirely. These treatments are marketed for everything from addiction recovery to jet lag to anti-aging. They are not FDA approved for any of these purposes.

The tolerability profile of IV NAD+ is notably worse than oral precursors. In a pilot study comparing IV NAD+ to IV NR, every participant receiving NAD+ reported moderate to severe abdominal cramping, diarrhea, nausea, vomiting, increased heart rate, throat pain, congestion, and chest pressure during the infusion. These symptoms stopped when the infusion ended, but they were universal and uncomfortable enough to raise questions about whether this delivery method makes practical sense.¹⁴

IV NAD+ clinics operate in a particularly unregulated space. Because they frame their services as wellness treatments rather than medical therapies for specific diseases, they largely avoid FDA oversight. There is no standardized protocol for dosing, infusion rate, or patient screening. The fact that a clinic offers something does not mean it has been vetted for safety or efficacy by any regulatory body.

Safety and the Cancer Question

For oral precursors, the safety profile across published trials is generally reassuring. A systematic review of NAD+ and its precursors across multiple clinical conditions found that the most common side effects were muscle pain, nervous system complaints, fatigue, sleep disturbance, and headaches. None of the adverse events cataloged posed a serious health risk.¹⁵ A trial testing NR at 3,000 mg per day, three times the dose in most supplements, in people with Parkinson’s disease found it was well tolerated over four weeks with no moderate or severe adverse events.¹⁶

The caveat is that all of these trials are short. We are talking about weeks to a few months. People taking NAD+ supplements often plan to take them for years or decades. Long-term safety data simply does not exist yet.

The most substantive concern involves cancer. NAD+ is central to energy metabolism, and cancer cells are famously energy-hungry. Researchers have flagged that artificially boosting NAD+ levels could theoretically feed existing tumors or support early malignant cells that the body might otherwise suppress. Some researchers have specifically called for more investigation into whether elevating NAD+ or overexpressing sirtuins could increase the potential for cancer or other age-related disease, given the high energy requirements of certain tumors.¹⁷ NAD+ plays a regulatory role in both aging and the development of malignancy, and those two processes share more biology than consumers typically realize.¹⁸

No human trial has shown that NAD+ supplements cause cancer. But no trial has been designed or powered to detect that signal, either. The trials are too small and too short. The theoretical concern remains open, and it is the kind of risk that would only become visible in large populations tracked over many years.

The Supplement Quality Problem

Even if you decide that the potential benefits of NAD+ precursors outweigh the uncertainties, there is a separate practical problem: you may not be getting what you pay for. Because supplements are not held to the same manufacturing standards as drugs, the contents of an NMN or NR capsule can vary wildly from what the label claims.

A study that tested commercially available NMN supplements found deviations from labeled amounts ranging from 28.6% over the stated dose to products containing none of the active ingredient at all, a spread of +28.6% to -100%.¹⁹ A separate analysis of eight NMN supplements using a more precise measurement method revealed substantial variation in isomer composition, with some products containing undeclared or inaccurately labeled ingredients.²⁰ The isomer issue matters because NMN exists in two forms (alpha and beta), and only beta-NMN is the biologically active form studied in trials.

This is not unique to NAD+ products. It is a system-wide problem with the supplement industry, but it is especially relevant here because the products are expensive, often running $40 to $100 or more per month, and consumers are making purchasing decisions based on label claims that may bear little relationship to what is inside the bottle. Third-party testing certifications can help, but they are voluntary and not universally adopted.

How to Think About NAD+ Products as a Consumer

The gap between what the science shows and what the marketing says is unusually wide for NAD+ products. The science shows that precursors raise blood NAD+ levels, that short-term use appears safe, and that small trials have found hints of metabolic and cardiovascular benefits. The marketing says these products reverse aging, restore youthful energy, enhance cognition, and protect against disease. Those claims go far beyond the evidence.

If you are considering an NAD+ precursor supplement, NR is the only major precursor that is both legal to sell as a supplement in the U.S. and backed by a reasonable number of human safety trials. NMN has a more complicated legal status and roughly similar clinical evidence. Niacin, the oldest and cheapest form of vitamin B3, also raises NAD+ but comes with flushing side effects at high doses and a long track record in cardiovascular medicine that does not clearly support anti-aging benefits.

For IV NAD+ therapy, the evidence for tolerability is poor and the evidence for efficacy is essentially nonexistent in controlled human trials. You are paying a premium for a delivery method that causes significant discomfort and has not been shown to produce outcomes that oral precursors cannot.

Newer Precursors on the Horizon

The NAD+ precursor landscape is not static. Researchers have identified reduced nicotinamide mononucleotide (NMNH), a chemically distinct molecule, as a potentially more potent precursor that raises NAD+ levels faster and to a higher degree than either NMN or NR in cell and animal studies. NMNH appears to work through a different metabolic pathway entirely.²¹ Whether this translates to better outcomes in people is unknown. NMNH has not yet been tested in human trials, let alone evaluated by the FDA.

The broader pattern in this field is that the basic biology of NAD+ is genuinely exciting and well supported, while the consumer-facing products have raced far ahead of the clinical evidence. NAD+ clearly plays a central role in aging at the cellular level, and restoring its levels in aged mice produces real improvements. But mice are not people, four-week trials are not lifetime data, and a supplement that raises a blood biomarker is not the same thing as a treatment that makes you healthier. The FDA has not approved any NAD+ product for any condition, and the current evidence does not suggest that approval is imminent for any anti-aging indication. That does not mean these molecules are useless. It means the honest answer is “we don’t know yet,” and anyone selling certainty is selling more than the science supports.